Sales Leader to Bring Years of Experience to Key Role within Commercial Operations

CARLSBAD, Calif.–Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced that it has named Jay Therrien to the position of Vice President, Global Sales for Next Generation Sequencing. In this role, Therrien will be responsible for all sales activities related to Life Technologies’ next generation sequencing portfolio.

Therrien most recently served as Director of Sales for Asia Pacific and Japan for Illumina Inc. He joined Illumina in 2004 as a Regional Account Manager and served in roles of progressively greater responsibility during his nearly six-year tenure with the company. Prior to joining Illumina, Therrien held positions as Senior Scientist and Director of Business Development for ACGT, Inc., and Technical Support Specialist and Field Application Specialist at Vysis, Inc. and Nanogen Inc. respectively. Therrien holds a doctorate from the University of Kansas and a Bachelor’s degree from the University of Illinois at Urbana-Champaign.

“I’m very pleased to have Jay join us in this key role,” said Bernd Brust, the company’s President and Chief Commercial Operations Officer. “Life Technologies is a leader in next generation sequencing, and I am confident that Jay’s talent, and his years of both scientific and sales experience, will only strengthen our capabilities and will allow us to further enhance our premier portfolio in this space.”

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.